MALAT1 and metastatic malignant neoplasm in the lymph nodes: To clarify whether MALAT1 could be a therapeutic target for HNSCC in vivo, we evaluated the potential clinical efficacy of MALAT1 depletion using a mouse model of lymph node metastasis.